The Centers for Disease Control and Prevention (CDC) has issued a Health Alert Network advisory highlighting an increased risk of severe arboviral neuroinvasive disease in patients undergoing B‑cell–depleting or B‑cell–modulating therapies, particularly those treated with anti‑CD20 monoclonal antibodies.

Clinicians and public health authorities are advised to be vigilant in monitoring these patients for signs of neuroinvasive arboviral infections, given their heightened susceptibility to more severe disease outcomes.

The advisory includes clinical guidance and recommended actions to support healthcare professionals in the timely identification and management of arboviral infections within this vulnerable patient population.

Awareness and adherence to the provided recommendations are essential to optimize patient care and mitigate the risks associated with arboviral diseases in this context.